BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Inven2 - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.inven2.com
X-WR-CALDESC:Arrangement for Inven2
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Oslo
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Oslo:20230214T083000
DTEND;TZID=Europe/Oslo:20230214T091500
DTSTAMP:20260421T223550
CREATED:20230117T110208Z
LAST-MODIFIED:20230131T165343Z
UID:11531-1676363400-1676366100@www.inven2.com
SUMMARY:Trends and Needs in Clinical Trials – Opportunities or Barriers for Norway?
DESCRIPTION:In this breakfast meeting we will address the major trends in clinical trials and discuss if this is an opportunity or a barrier for Norway to be competitive in attracting more clinical trials. \nSome of the biggest changes that are expected to happen in the clinical trials industry in next couple of years are going to be driven by technology. Digital platforms and smart applications are going to be used to procure informed consent from the participants\, store information\, and conduct other critical tasks.  The growing ability of AI to probe patient data—including medical histories\, labs\, scans\, clinician notes\, and other documentation—points to the growing role that RWD will play in health innovation moving forward. \nIn this breakfast meeting we will address the major trends in clinical trials and discuss if this is an opportunity or a barrier for Norway to be competitive in attracting more clinical trials. \nGo to registration: https://lmi.pameldingssystem.no/trends-and-needs-in-clinical-trials-ndash-opportunities-or-barriers-for-norway  \nPROGRAM \nModerator: Kirsti Nyhus\, CEO and Market access director in AbbVie \nTrends and needs in Clinical Trials\, Andreas Heddini\, Vice President Medical and Regulatory Affairs\, Nordics\, AstraZeneca \nClinical trials in Norway today\, Siri Kolle Vice President Clinical\, Inven2 \nComments/Panel discussion: \nWhat are the opportunities for Clinical Trials in Norway given the global trends and what priorities do we have to make to increase clinical trial activity in Norway? \nParticipants: \nKarl Kristian Bekeng\, State Secretary\, The Ministry of Health and Care Services (HOD) \nFredrik Schjesvold\, Head of Oslo Myeloma Center; PhD\, MD Oslo University Hospital \nPeder Langeland Myhre Førsteamanuensis – Klinikk for indremedisin og lab fag\, Akershus universitetssykehus
URL:https://www.inven2.com/arrangement/breakfast-meeting-trends-and-needs-in-clinical-trials-opportunities-or-barriers-for-norway/
LOCATION:Meet\, Sognsveien 75\, Oslo\, Oslo\, 0840\, Norge
CATEGORIES:Kliniske studier
ATTACH;FMTTYPE=image/jpeg:https://www.inven2.com/wp-content/uploads/2022/03/shutterstock_1213031050-scaled.jpg
END:VEVENT
END:VCALENDAR